{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039170","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.157223+00:00","generated_at":"2026-06-09T00:39:17.785725+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vivos raises $4.0M via private placement of stock and warrants; amends prior warrant","bullets":["Sold 980,393 shares (or pre-funded warrants) at $4.08/share plus 980,393 Series A and 980,393 Series B warrants at $3.83.","Net proceeds of ~$3.5M for working capital and corporate purposes.","Amended January 2023 warrant held by same investor: exercise price cut from $30 to $3.83, expiration extended to Nov 2, 2028.","Registration rights agreement requires filing within 20 days; penalties up to 10.5% of gross proceeds for delay.","A.G.P./Alliance Global Partners acted as placement agent with 7% cash fee."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039170","json":"https://secwatch.observer/filing/0001493152-23-039170.json","markdown":"https://secwatch.observer/filing/0001493152-23-039170.md","text":"https://secwatch.observer/filing/0001493152-23-039170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223039170/0001493152-23-039170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223039170/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:39:17.785725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1267cc63aaed89b24155e3ba4a687111d36cc11e","claim":"Vivos Therapeutics, Inc. amended January 2023 Warrant Amendment with the Purchaser (effective 2023-11-02).","evidence_excerpt":"Such amendment (the “ January 2023 Warrant Amendment ”), which became effective upon the closing of the Private Placement, reduced the exercise price of the January 2023 Warrant to $3.83 per share and extended the expiration date of the January 2023 Warrant to November 2, 2028.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223039170/0001493152-23-039170-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Purchaser"},{"label":"Effective","value":"2023-11-02"}],"fact_type":"material_agreement"},{"claim_id":"38aa666acbb77d0cbd1f1c4a9673927c5f7b842a","claim":"Vivos Therapeutics, Inc. entered into Registration Rights Agreement with the Purchaser (effective 2023-11-02).","evidence_excerpt":"On the Closing Date, in connection with the Private Placement, the Company entered into a registration rights agreement with the Purchaser (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission (the “ SEC ”) covering the resale of the Shares and the shares of Common Stock issuable upon exercise of the Warrants within 20 days of the Closing Date","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223039170/0001493152-23-039170-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Purchaser"},{"label":"Effective","value":"2023-11-02"}],"fact_type":"material_agreement"},{"claim_id":"95d1cae489b717699cadd0ea1066ca22d3635841","claim":"Vivos Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2023-10-30).","evidence_excerpt":"Pursuant to a placement agency agreement dated October 30, 2023, between the Company and the Placement Agent (the “ Placement Agency Agreement ”), the Company agreed to pay to the Placement Agent a cash fee equal to 7.0% of the gross proceeds received by the Company in the Private Placement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223039170/0001493152-23-039170-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"},{"claim_id":"ee2a8a937ed5b5803d4960aa7bc5c08b516a2ccc","claim":"Vivos Therapeutics, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $4,000,003.44 (effective 2023-10-30).","evidence_excerpt":"On October 30, 2023, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Purchaser ”) pursuant to which the Company agreed sell an aggregate of $4,000,003.44 of securities of the Company in a private placement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315223039170/0001493152-23-039170-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"$4,000,003.44"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}